These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 9351545

  • 1. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
    Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H, Kitahara S.
    Cancer; 1997 Nov 01; 80(9):1760-7. PubMed ID: 9351545
    [Abstract] [Full Text] [Related]

  • 2. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M, Noda S.
    J Urol; 2001 Sep 01; 166(3):1106-10. PubMed ID: 11490307
    [Abstract] [Full Text] [Related]

  • 3. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C.
    J BUON; 2009 Sep 01; 14(3):463-72. PubMed ID: 19810140
    [Abstract] [Full Text] [Related]

  • 4. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y, Ochi M, Tokue A.
    Hinyokika Kiyo; 2000 Dec 01; 46(12):869-72. PubMed ID: 11211802
    [Abstract] [Full Text] [Related]

  • 5. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
    Akimoto S, Akakura K, Shimazaki J.
    Jpn J Clin Oncol; 1996 Jun 01; 26(3):157-63. PubMed ID: 8656556
    [Abstract] [Full Text] [Related]

  • 6. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M, Jonas D, Oremek GM.
    Anticancer Res; 2009 Feb 01; 29(2):671-3. PubMed ID: 19331219
    [Abstract] [Full Text] [Related]

  • 7. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T, Sakai H, Kanetake H, Saito Y.
    Hinyokika Kiyo; 1999 Apr 01; 45(4):235-9. PubMed ID: 10363141
    [Abstract] [Full Text] [Related]

  • 8. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R, Thölix E.
    Anticancer Res; 1996 Apr 01; 16(4B):2289-93. PubMed ID: 8694558
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M, Takahashi S, Ogata E.
    Anticancer Res; 2003 Apr 01; 23(5b):4095-9. PubMed ID: 14666607
    [Abstract] [Full Text] [Related]

  • 14. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A.
    Cancer Epidemiol Biomarkers Prev; 1993 Apr 01; 2(2):125-9. PubMed ID: 8467247
    [Abstract] [Full Text] [Related]

  • 15. [Clinical usefulness of blood PICP, PINP and ICTP concentrations as bone metastasis markers in prostate cancer patients].
    Kobayashi Y, Tokue A.
    Nihon Rinsho; 1998 Aug 01; 56(8):2072-6. PubMed ID: 9750510
    [Abstract] [Full Text] [Related]

  • 16. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W, Muley T, Herb KP, Schmidt-Gayk H.
    Anticancer Res; 2004 Aug 01; 24(5B):3193-201. PubMed ID: 15510610
    [Abstract] [Full Text] [Related]

  • 17. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R, Rossi S, Caniggia M, Pozzessere D, Messinese S, Sabatino M, Marsili S, Correale P, Salvestrini F, Manganelli A, Francini G.
    Urology; 2004 Feb 01; 63(2):321-6. PubMed ID: 14972482
    [Abstract] [Full Text] [Related]

  • 18. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 19. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, Parpala T, Risteli J, Breit SN, Jukkola-Vuorinen A.
    Cancer Epidemiol Biomarkers Prev; 2007 Mar 15; 16(3):532-7. PubMed ID: 17372249
    [Abstract] [Full Text] [Related]

  • 20. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer.
    Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, Noma H, Kumazawa J.
    Prostate; 1999 Apr 01; 39(1):1-7. PubMed ID: 10221259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.